Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Immunopharmacol ; 17(4): 291-302, 1995 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7672880

RESUMO

This study was undertaken to assess the optimum conditions required to reduce the vigorous host granulomatous reaction around Schistosoma mansoni eggs. Soluble schistosomal egg antigen (SEA) at a concentration of 10 or 100 micrograms protein was administered i.p. or i.v. into unprimed C57BL/6 mice. SEA was injected either alone or in combination with cyclophosphamide (CY) 100 or 50 mg/kg via i.p. route. Seven or 14 days later viable eggs of S. mansoni were injected via the tail vein into treated groups and untreated normal controls. Mice were sacrificed 8, 16 and 24 days after the injection of eggs. The lungs were removed for histopathological study, measurement of granuloma diameter and phenotypic analysis of granuloma intralesional T-cell subsets. Compared to untreated controls, the lower concentration of SEA (10 micrograms) administered by the i.v. route 7 days before egg injection, induced a significant reduction in granuloma diameter 16 days after egg injection than that by the i.p. route or at a higher SEA concentration (100 micrograms). Compared to untreated controls, the higher dose of CY (100 mg/kg), given i.p. alone or in combination with 10 micrograms SEA by the i.v. or i.p. route, induced a significant reduction in granuloma diameter, while 50 mg/kg CY did not cause any reduction. The reduction in granuloma diameter by i.v. administration of low SEA concentration alone or in combination with CY IP, was associated with a decrease in the granuloma intralesional L3T4+/Lyt2+ ratio. The decrease in the ratio was due to an increase in Lyt2+ cells. The results suggest that the use of low dose SEA by the i.v. route alone or combined with an immunosuppressive drug ameliorates pathological changes concurrent with S. mansoni infection.


Assuntos
Antígenos de Helmintos/uso terapêutico , Dessensibilização Imunológica , Granuloma/prevenção & controle , Proteínas de Helminto , Pneumopatias Parasitárias/prevenção & controle , Schistosoma mansoni/imunologia , Esquistossomose mansoni/imunologia , Animais , Antígenos de Helmintos/administração & dosagem , Antígenos de Helmintos/imunologia , Ciclofosfamida/uso terapêutico , Granuloma/imunologia , Granuloma/patologia , Interações Hospedeiro-Parasita , Injeções Intraperitoneais , Injeções Intravenosas , Pneumopatias Parasitárias/imunologia , Pneumopatias Parasitárias/patologia , Camundongos , Camundongos Endogâmicos C57BL , Esquistossomose mansoni/patologia , Subpopulações de Linfócitos T/efeitos dos fármacos , Subpopulações de Linfócitos T/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...